ESMO 2024 | Promising outcomes of sunitinib and nivolumab in clear cell sarcoma
Javier Martin-Broto, MD, PhD, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain, highlights promising data from the IMMUNOSARC II trial (NCT03277924) of sunitinib with nivolumab in a clear cell sarcoma cohort. This regimen shows encouraging progression-free survival and overall survival. While early, these findings support incorporating immunomodulation into clear cell sarcoma treatment. However, understanding why not all patients benefit and identifying viable second-line options remain significant challenges. This interview took place at the European Society for Medical Oncology (ESMO) 2024 Congress in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
